

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 May 2002 (23.05.2002)

PCT

(10) International Publication Number
WO 02/39980 A2

- (51) International Patent Classification⁷: **A61K 9/00**
- (21) International Application Number: **PCT/SI01/00031**
- (22) International Filing Date:
20 November 2001 (20.11.2001)
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
P-200000282 20 November 2000 (20.11.2000) **SI**
- (71) Applicant (for all designated States except US): **LEK, TOVARNA FARMACEVTSKIH IN KEMIENIH IZDELKOV, D.D. [SI/SI];** Verovškova 57, 1526 Ljubljana (SI).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **SIRCA, Judita** [SI/SI]; Gašperčičeva 7, 1000 Ljubljana (SI).
- (74) Agent: **PATENTNA PISARNA, D.O.O.**; Copova 14, POB 1725, 1001 Ljubljana (SI).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/39980 A2

(54) Title: **NOVEL PHARMACEUTICAL FORMULATION IN THE FORM OF CELLULOSE CAPSULES SUITABLE FOR BENZIMIDAZOLE DERIVATIVES**

(57) Abstract: Described is a novel pharmaceutical formulation in the form of a capsule for oral use, which consists of a cellulose derivative as the base and enteric coating pellets, manufactured by anhydrous granulation of a therapeutically effective amount of an active substance that is a benzimidazole derivative and of dried pharmaceutically acceptable excipients, whereat all used pharmaceutically acceptable excipients are, prior to use, dried in such a manner that their moisture content is less than 1 %.

BEST AVAILABLE COPY

NOVEL PHARMACEUTICAL FORMULATION IN THE FORM OF CELLULOSE CAPSULES SUITABLE FOR BENZIMIDAZOLE DERIVATIVES

Technical Field of the Invention

(IPC: A 61J 3/07, C07D 235/04)

The invention belongs to the field of pharmaceutical technology and relates to the use of hard capsules for active substances that have poor water solubility, quickly disintegrate in an acidic medium and are unstable in the presence of moisture, solvents and acidic substances, whereas they have good stability in a neutral or alkaline medium, are quickly absorbed and metabolized and have an extended period of action. More precisely, the present invention relates to the use of hard capsules containing cellulose derivatives as the base, for the preparation of a pharmaceutical form with controlled release of active substances which are benzimidazole derivatives.

Technical Problem

There exists a constant need for the preparation of pharmaceutical formulations in the form of capsules, by which, in a technologically simple manner, a good stability of active substances that have poor water solubility, quickly disintegrate in an acidic medium and are unstable in the presence of moisture, solvents and acidic substances, whereas they have good stability in a neutral or an alkaline medium, are quickly absorbed and metabolized and have an extended period of action, is achieved. Hitherto known pharmaceutical formulations in the form of capsules containing such active substances use enteric coating pellets filled into hard gelatin capsules for providing a suitable stability of the active substance. These capsules have the disadvantage that they contain 13 to 15 wt. % of water. Therefore an additional drying of the capsules filled with enteric coating pellets is necessary.

Prior Art

In US 5,264,223 and US 5,431,917 hard capsules containing water-soluble cellulose derivative as the base, a gel-forming agent and a gelling additive are described. An advantage of the described capsules is that they are less brittle in conditions of lower humidity.

In US 5,756,123 hard gelatin capsules containing a water-soluble cellulose derivative such as hydroxypropylmethyl cellulose (HPMC) as the base are described. The main advantage of the described capsules is the use of the water-soluble cellulose derivative HPMC as the base, which does not disintegrate under special conditions (e.g. after consuming milk products).

In the article of T. Ogura, Y. Furuya, S. Matsuura (Pharmaceutical Technology Europe, November 1998, Volume 10, Number 11, pp. 32-42), a comparison between gelatin and HPMC capsules is described. It is stated that HPMC capsules are, *inter alia*, also suitable for active substances that are unstable in water. For active substances that are extremely sensitive to moisture, however, in order to increase their stability, pharmaceutically acceptable excipients absorbing water have to be added to the pharmaceutical formulation and an additional drying agent to the package nevertheless.

In WO 99/03453 there is described a novel pharmaceutical formulation with controlled release of active substances that are unstable in an acidic medium, unstable at extended storage in the presence of water and at the same time sensitive to heating, which is prepared by anhydrous granulation of active substances and additionally dried pharmaceutically acceptable substances with all pharmaceutically acceptable excipients dried prior to use in such a manner that their moisture content is lower than 1.0 %, preferably lower than 0.5 %. Enteric coating pellets are then filled into hard gelatin capsules.

Description of Solution to Technical Problem with Examples

The invention is based upon the task to prepare a novel pharmaceutical formulation with active substances that have poor water solubility, quickly disintegrate in an acidic medium and are unstable in the presence of moisture, solvents and acidic substances, whereas they have good stability in a neutral or alkaline medium, are quickly absorbed and metabolized and have an extended period of action. In the narrow sense, the invention deals with a pharmaceutical formulation in which enteric coating pellets are filled into hard cellulose capsules consisting of a water-soluble cellulose derivative, preferably hydroxypropylmethyl cellulose (HPMC) as the base.

It has surprisingly been found that cellulose capsules are also suitable for active substances that have poor water solubility, quickly disintegrate in an acidic medium and are unstable in the presence of moisture, solvents and acidic substances, whereas they have good stability in a neutral or alkaline medium, are quickly absorbed and metabolized and have an extended period of action. It has to be pointed out that into the inventive pharmaceutical formulation as such, no pharmaceutically acceptable excipient absorbing water has to be added nor does any additional drying agent have to be inserted into the package.

In comparison to hard gelatin capsules, the technological process with cellulose capsules simplifies and shortens the technological process of manufacturing a pharmaceutical formulation according to the invention, since there is no need for any additional drying of already filled capsules to achieve the same stability of the active substances as by using hard gelatin capsules. The process of drying hard gelatin capsules lasts from 15 to 20 hours, which means that during all this time the active substance, which is poorly water-soluble and unstable in the presence of moisture, is exposed to the humid environment of the gelatin capsule.

By the use of cellulose capsules where drying is not necessary, the complete process of manufacturing the pharmaceutical formulation according to the invention is shortened, which is of essential importance with active substances that are poorly

water-soluble, quickly disintegrate in an acidic medium and are unstable in the presence of moisture, solvents and acidic substances. Drying is an energy-consuming process, therefore the omission of drying saves large amounts of energy. Additionally, by the use of cellulose capsules instead of hitherto common hard gelatin capsules more production series of the final product can be made within the same period of time.

Pharmaceutical formulation according to the invention, wherein enteric coating pellets are filled into cellulose capsules, is especially suitable for active substances such as benzimidazole derivatives, which are known as substances that have poor water solubility, quickly disintegrate in an acidic medium and are unstable in the presence of moisture, solvents and acidic substances, whereas they have good stability in a neutral or alkaline medium, are quickly absorbed and metabolized and have an extended period of action. As active substances various benzimidazole derivatives can be used such as omeprazole, lansoprazole, timoprazole, rabeprazole, pantoprazole, leminoprazole, pariprazole, esomeprazole and their pharmaceutically acceptable salts such as sodium and magnesium salts. Active substances may also be in the form of their optical isomers and their pharmaceutically acceptable salts such as sodium and magnesium salts. These active substances are known as proton pump inhibitors and are used in the treatment of gastrointestinal diseases.

Enteric coating pellets to be filled in cellulose capsules are prepared according to a process of anhydrous granulation of active substances and of additionally dried pharmaceutically acceptable excipients, which are, prior to use, dried in such a manner that their moisture content is less than 1.0 %, preferably less than 0.5 %. The composition of enteric coating pellets and the manufacture thereof are described in WO 99/03453. Enteric coating pellets may be filled into cellulose capsules on all known capsulating machines that are usually used for filling pellets into hard gelatin capsules.

The invention is illustrated but in no way limited by the following working examples.

Example 1:

a) Pellet cores

Composition for 1000 g of pellet cores.

Omeprazole	100 g
Low substituted hydroxypropylcellulose (13 to 16 % of hydroxypropoxy groups)	150 g
Microcrystalline cellulose	150 g
Mannitol	478 g
Sodium cross-linked carboxymethylcellulose	50 g
Polyvinylpyrrolidone K 25	70 g
Polyoxyethylated hydrogenated castor oil	2 g

The used pharmaceutically acceptable excipients were, prior to use, dried in such a manner that their moisture content was less than 1.0 %, preferably less than 0.5 %.

A series of 1000 g of pellet cores was prepared according to the following process:

2 g of polyoxyethylated hydrogenated castor oil (Cremophor® RH 40) was dissolved at room temperature in 300 g of absolute ethanol. At room temperature, the formed solution (302 g) was dispersed in a fluidized bed granulator onto previously prepared homogeneous mixture of powder components 100 g of omeprazole, 150 g of dried low-substituted hydroxypropylcellulose (L-HPC LH-20), 150 g of dried microcrystalline cellulose, 478 g of dried mannitol, 50 g of dried sodium cross-linked carboxymethylcellulose and 70 g of dried polyvinylpyrrolidone K 25. So prepared plastic mixture was extruded and than spheronized. The formed pellet cores were dried in a fluidized bed or in a chamber dryer at a temperature of inlet air from 35 to 45°C, until the moisture content was less than 0.5 %.

In such a manner 1000 g of pellet cores were obtained.

b) Enteric coating pellets

Pellet cores	1000 g
Hydroxypropylmethyl cellulose phthalate	150 g
Dibutyl sebacate	15 g

150 g of hydroxypropylmethyl cellulose phthalate and 15 g of dibutyl sebacate were dissolved at room temperature in a mixture of 1754 g of absolute ethanol and 438 g of acetone. The prepared solution was sprayed onto pellet cores in a fluidized bed apparatus.

c) Capsulation

On a capsulating machine with gravimetrical filling the manufactured enteric coating pellets were filled into cellulose capsules Qualicaps Shionogi (cellulose capsules containing hydroxypropylmethyl cellulose as the cellulose derivative) with the content of omeprazole amounting to 20 mg/capsule.

Example 2:**a) Pellet cores**

Composition for 1000 g of pellet cores:

Lansoprazole	100 g
Microcrystalline cellulose	200 g
Mannitol	598 g
Sodium starch glycolate	50 g
Polyvinylpyrrolidone K 25	50 g
Polysorbate 80	2 g

The used pharmaceutically acceptable excipients were, prior to use, dried in such a manner that their moisture content was less than 1.0 %, preferably less than 0.5 %.

Pellet cores were prepared according to the same process as in the Example 1 with exception that the active substance omeprazole was replaced by lansoprazole, dried low-substituted hydroxypropylcellulose (L-HPC LH-20) was replaced by microcrystalline cellulose, sodium cross-linked carboxymethylcellulose was replaced by sodium starch glycolate and the surfactant polyoxyethylated hydrogenated castor oil (Cremophor® RH 40) was replaced by Polysorbate 80.

b) Enteric coating pellets

Pellet cores	1000 g
Eudragit L 100	150 g
Dibutyl sebacate	22 g
Talc	15 g

150 g of Eudragit and 22 g of dibutyl sebacate were dissolved at room temperature in 1325 g of absolute ethanol and 15 g of talc were dispersed. Under constant stirring the prepared suspension was sprayed onto pellet cores in an apparatus with fluidized air.

c) Capsulation

On a capsulating machine with gravimetric filling the manufactured enteric coating pellets were filled into cellulose capsules Qualicaps Shionogi (cellulose capsules containing hydroxypropylmethyl cellulose as a cellulose derivative) with the content of lansoprazole amounting to 20 mg/capsule.

Example 3

Comparison of pharmaceutical formulations in the form of gelatin capsules and cellulose capsules and advantages of the use of cellulose capsules

a) Preparation of pharmaceutical formulation

For the comparative test enteric coating pellets were prepared according to the process described in Example 1, points a) and b), whereupon, on a capsulating machine with gravimetric filling, some were filled into hard gelatin capsules and others into cellulose capsules Qualicaps Shionogi (the cellulose derivative was hydroxypropylmethyl cellulose).

b) Drying of pharmaceutical formulation

In the technological process of manufacturing the pharmaceutical formulation this phase took place immediately after capsulating.

Table 1: Comparison of drying time of capsules in the technological process of manufacturing the pharmaceutical formulation

Capsules used	Pharmaceutical formulation using hard gelatin capsules	Pharmaceutical formulation using cellulose capsules
Drying time	15-20 hours	0 hours

c) Stability of active substance

Table 2: Comparison of stability of pharmaceutical forms

Capsules used	Pharmaceutical formulation using hard gelatin capsules	Pharmaceutical formulation using cellulose capsules
Related substances and disintegration products after 3 months at conditions of 40 °C and 75% relative humidity	1.10 %	1.09 %

Determination of related substances and disintegration products

Principle

HPLC determination

Chromatography conditions

- stationary phase

Symmetry C8

- dimensions:

150 x 4.6 mm

- temperature:

30°C or controlled room temperature,

Mobile phase:

buffer : acetonitrile

300 : 100, vol. ratio,

Flow:

0.8 ml/min,

Injection volume

50 µl

Wave length

UV, 320 nm.

From the above tables it is evident that in comparison with the hard gelatin capsules the use of cellulose capsules does not impair the stability of the active substance, yet it brings big savings in the technological process due to the omission of the long drying phase (energy savings, larger production capacity).

A great advantage of the use of cellulose capsules is also the fact that the active substance that is unstable in the presence of moisture is not exposed to the humid environment of the gelatin capsule for a lengthy period of time.

Into the pharmaceutical formulation according to the invention that is manufactured according to the process of anhydrous granulation of the active substance and of dried pharmaceutically acceptable excipients, no pharmaceutically acceptable water-absorbing excipient has to be added. Due to the smaller number of excipients the novel pharmaceutical formulation puts less strain on the patient's organism.

No drying agent has to be added into the final package.

The capsulating of the pharmaceutical formulation with cellulose capsules according to the invention is performed on the same equipment i.e. the same capsulating machines as with hard gelatin capsules.

Claims

1. A capsule for oral use, characterized in that it consists of a cellulose derivative as the base and that the active substance is a benzimidazole derivative.
2. A capsule for oral use according to claim 1, characterized in that the cellulose derivative is hydroxypropylmethyl cellulose.
3. A capsule for oral use according to claim 1, characterized in that the benzimidazole derivative is selected from a group comprising omeprazole, lansoprazole, timoprazole, rabeprazole, pantoprazole, leminoprazole, pariprazole, esomeprazole, their pharmaceutically acceptable salts, their optically active isomers and pharmaceutically acceptable salts thereof.
4. A capsule for oral use according to claim 3, characterized in that the active substance is omeprazole or its pharmaceutically acceptable salt.
5. A capsule for oral use according to claim 3, characterized in that the active substance is an optically active isomer of omeprazole or a pharmaceutically acceptable salt thereof.
6. A capsule for oral use according to claim 3, characterized in that the active substance is lansoprazole or its pharmaceutically acceptable salt.
7. A capsule for oral use according to claim 3, characterized in that the active substance is an optically active isomer of lansoprazole or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical formulation in the form of a capsule for oral use, characterized in that it contains:
 - a) a capsule consisting of a cellulose derivative as the base and

- b) enteric coating pellets manufactured by anhydrous granulation of a therapeutically effective amount of an active substance that is a benzimidazole derivative and of dried pharmaceutically acceptable excipients.
9. A pharmaceutical formulation in the form of a capsule for oral use according to claim 8, characterized in that the cellulose derivative is hydroxypropylmethyl cellulose.
 10. A pharmaceutical formulation in the form of a capsule for oral use according to claim 8, characterized in that the benzimidazole derivative is selected from a group comprising omeprazole, lansoprazole, timoprazole, rabeprazole, pantoprazole, leminoprazole, pariprazole, esomeprazole, their pharmaceutically acceptable salts, their optically active isomers and pharmaceutically acceptable salts thereof.
 11. A pharmaceutical formulation in the form of a capsule for oral use according to claim 10, characterized in that the active substance is omeprazole or its pharmaceutically acceptable salt.
 12. A pharmaceutical formulation in the form of a capsule for oral use according to claim 10, characterized in that the active substance is an optically active isomer of omeprazole or a pharmaceutically acceptable salt thereof.
 13. A pharmaceutical formulation in the form of a capsule for oral use according to claim 10, characterized in that the active substance is lansoprazole or its pharmaceutically acceptable salt.
 14. A pharmaceutical formulation in the form of a capsule for oral use according to claim 10, characterized in that the active substance is an optically active isomer of lansoprazole or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical formulation in the form of a capsule for oral use according to claim 8, characterized in that all used pharmaceutically acceptable excipients are, prior to use, dried in such a manner that their moisture content is less than 1 %.
16. A pharmaceutical formulation in the form of a capsule for oral use according to claim 15, characterized in that all used pharmaceutically acceptable excipients are, prior to use, dried in such a manner that their moisture content is less than 0.5 %.
17. A process for the preparation of a pharmaceutical formulation in the form of a capsule for oral use according to claims 8 to 16, characterized in that enteric coating pellets are filled into capsules consisting of a cellulose derivative as the base.
18. A process for the preparation of a pharmaceutical formulation in the form of a capsule for oral use according to claim 17, characterized in that the cellulose derivative is hydroxypropylmethyl cellulose.
19. A pharmaceutical formulation in the form of a capsule for oral use according to claims 8 to 16, characterized in that it is used for the treatment of gastrointestinal diseases.
20. A method of treatment of gastrointestinal diseases comprising administering to patients suffering from gastrointestinal diseases a pharmaceutical formulation in the form of a capsule for oral use which contains:
 - a) a capsule consisting of a cellulose derivative as the base and
 - b) enteric coating pellets manufactured by anhydrous granulation of a therapeutically effective amount of an active substance that is a benzimidazole derivative and of dried pharmaceutically acceptable excipients.
21. A method of treatment of gastrointestinal diseases according to claim 20, characterized in that the cellulose derivative is hydroxypropylmethyl cellulose.

22. A method of treatment of gastrointestinal diseases according to claim 20, characterized in that the benzimidazole derivative is selected from a group comprising omeprazole, lansoprazole, timoprazole, rabeprazole, pantoprazole, leminoprazol, pariprazole, esomeprazole, their pharmaceutically acceptable salts, their optically active isomers and pharmaceutically acceptable salts thereof.
23. A method of treatment of gastrointestinal diseases according to claim 22, characterized in that the active substance is omeprazole or its pharmaceutically acceptable salt.
24. A method of treatment of gastrointestinal diseases according to claim 22, characterized in that the active substance is an optically active isomer of omeprazole or a pharmaceutically acceptable salt thereof.
25. A method of treatment of gastrointestinal diseases according to claim 22, characterized in that the active substance is lansoprazole or its pharmaceutically acceptable salt.
26. A method of treatment of gastrointestinal diseases according to claim 22, characterized in that the active substance is an optically active isomer of lansoprazole or a pharmaceutically acceptable salt thereof.
27. A method of treatment of gastrointestinal diseases according to claim 20, characterized in that all used pharmaceutically acceptable excipients are, prior to use, dried in such a manner that their moisture content is less than 1 %.
28. A method of treatment of gastrointestinal diseases according to claim 27, characterized in that all used pharmaceutically acceptable excipients are, prior to use, dried in such a manner that their moisture content is less than 0.5 %.

29. A use of a pharmaceutical formulation in the form of a capsule for oral use for treatment of gastrointestinal diseases, characterized in that the pharmaceutical formulation contains:
- a) a capsule consisting of a cellulose derivative as the base and
 - b) enteric coating pellets manufactured by anhydrous granulation of a therapeutically effective amount of an active substance that is a benzimidazole derivative and of dried pharmaceutically acceptable excipients.
30. A use of a pharmaceutical formulation in the form of a capsule for oral use according to claim 29, characterized in that the cellulose derivative is hydroxypropylmethyl cellulose.
31. A use of a pharmaceutical formulation in the form of a capsule for oral use according to claim 29, characterized in that the benzimidazole derivative is selected from a group comprising omeprazole, lansoprazole, timoprazole, rabeprazole, pantoprazole, leminoprazole, pariprazole, esomeprazole, their pharmaceutically acceptable salts, their optically active isomers and pharmaceutically acceptable salts thereof.
32. A use of a pharmaceutical formulation in the form of a capsule for oral use according to claim 31, characterized in that the active substance is omeprazole or its pharmaceutically acceptable salt.
33. A use of a pharmaceutical formulation in the form of a capsule for oral use according to claim 31, characterized in that the active substance is an optically active isomer of omeprazole or a pharmaceutically acceptable salt thereof.
34. A use of a pharmaceutical formulation in the form of a capsule for oral use according to claim 31, characterized in that the active substance is lansoprazole or its pharmaceutically acceptable salt.

35. A use of a pharmaceutical formulation in the form of a capsule for oral use according to claim 31, characterized in that active substance is an optically active isomer of lansoprazole or a pharmaceutically acceptable salt thereof.
36. A use of a pharmaceutical formulation in the form of a capsule for oral use according to claim 29, characterized in that all used pharmaceutically acceptable excipients are, prior to use, dried in such a manner that their moisture content is less than 1 %.
37. A use of a pharmaceutical formulation in the form of a capsule for oral use according to claim 36, characterized in that all used pharmaceutically acceptable excipients are, prior to use, dried in such a manner that their moisture content is less than 0.5 %.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 May 2002 (23.05.2002)

PCT

(10) International Publication Number
WO 02/039980 A3

(51) International Patent Classification⁷: **A61K 9/48**,
31/454, A61P 1/00

(21) International Application Number: PCT/SI01/00031

(22) International Filing Date:
20 November 2001 (20.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P-200000282 20 November 2000 (20.11.2000) SI

(71) Applicant (for all designated States except US): **LEK, TOVARNA FARMACEVTSKIH IN KEMIENIH IZDELKOV, D.D.** [SI/SI]; Verovškova 57, 1526 Ljubljana (SI).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **SIRCA, Judita** [SI/SI]; Gašperšičeva 7, 1000 Ljubljana (SI).

(74) Agent: **PATENTNA PISARNA, D.O.O.**; Copova 14, POB 1725, 1001 Ljubljana (SI).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
11 July 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CAPSULE OF CELLULOSE DERIVATIVES SUCH AS HPMC CONTAINING BENZIMIDAZOLE DERIVATIVES SUCH AS OMEPRAZOLE

(57) Abstract: Described is a novel pharmaceutical formulation in the form of a capsule for oral use, which consists of a cellulose derivative as the base and enteric coating pellets, manufactured by anhydrous granulation of a therapeutically effective amount of an active substance that is a benzimidazole derivative and of dried pharmaceutically acceptable excipients, whereat all used pharmaceutically acceptable excipients are, prior to use, dried in such a manner that their moisture content is less than 1 %.



WO 02/039980 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/SI 01/00031

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/48 A61K31/454 A61P1/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	EP 1 072 258 A (GREITHER PETER) 31 January 2001 (2001-01-31) whole document, in particularly: claims 1,2,4	1-19, 29-37
X	EP 0 960 620 A (RANBAXY LAB LTD) 1 December 1999 (1999-12-01)	1-14, 17-19, 29-35
Y	whole document, in particularly: claims 1,25-27 page 3, line 1-7 page 5, line 34-36	15,16, 36,37
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

22 March 2002

Date of mailing of the international search report

08/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Luangkhot, N

INTERNATIONAL SEARCH REPORT

International Application No

PLI/SI 01/00031

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 99 03453 A (LEK TOVARNA FARMACEVTSKIH ;REBIC LJUBOMIRA BARBARA (SI); KOFLER BO) 28 January 1999 (1999-01-28) cited in the application whole document, in particularly: claims 1-3,5-8,30,31,37 page 3, line 16,17 page 7, line 28 -page 8, line 3 page 10, line 6-21 page 13, line 3-28 page 13, line 20-27 -page 4, line 2</p>	1-19, 29-37
Y	<p>T. OGURA, Y. FURUYA, M. MAATSUURA: "HPMC Capsules-An Alternative to Gelatin" PHARMACEUTICAL TECHNOLOGY EUROPE, vol. 10, no. 11, November 1998 (1998-11), pages 32-42, XP001062392 cited in the application whole document, in particularly: * conclusion * abstract</p>	1-19, 29-37
Y	<p>EP 0 496 437 A (HAESSLE AB) 29 July 1992 (1992-07-29) whole document, in particularly: page 5, line 1-3; claims 1,2,8</p>	1-19, 29-37
Y	<p>WO 96 24375 A (ASTRA AB ;DEPUI HELENE (SE); ROSINSKI ADAM (SE)) 15 August 1996 (1996-08-15) whole document, in particularly: page 5, line 11; claims 1,3,5,6,22; examples 9-12,14 page 2, line 16-22 page 18, line 2</p>	1-19, 29-37
Y	<p>US 5 431 917 A (YAMAMOTO TAIZO ET AL) 11 July 1995 (1995-07-11) cited in the application whole document, in particularly: column 2, line 30-38; claims 1,4; table 1 column 1, line 41-48</p>	1-19, 29-37

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC1/SI 01/00031

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1072258	A	31-01-2001	EP 1072258 A1	31-01-2001
EP 0960620	A	01-12-1999	AU 1979699 A	13-12-1999
			BR 9910723 A	12-06-2001
			CN 1237415 A	08-12-1999
			EP 0960620 A1	01-12-1999
			WO 9961022 A1	02-12-1999
			ZA 9810765 A	06-08-1999
WO 9903453	A	28-01-1999	SI 9700186 A	28-02-1999
			AU 8252398 A	10-02-1999
			EP 1003487 A1	31-05-2000
			PL 338010 A1	25-09-2000
			WO 9903453 A1	28-01-1999
EP 0496437	A	29-07-1992	GB 2189698 A	04-11-1987
			SG 154294 G	17-03-1995
			AT 84215 T	15-01-1993
			EP 0496437 A2	29-07-1992
			GR 3020734 T3	30-11-1996
			LV 5760 A4	20-12-1996
			AR 240250 A1	30-03-1990
			AT 140387 T	15-08-1996
			AT 184482 T	15-10-1999
			AU 601974 B2	27-09-1990
			AU 7191287 A	05-11-1987
			CA 1292693 A1	03-12-1991
			CN 87103284 A ,B	11-11-1987
			CY 1810 A	20-10-1995
			DD 273197 A5	08-11-1989
			DE 3751860 D1	22-08-1996
			DE 3751860 T2	21-11-1996
			DE 3783394 D1	18-02-1993
			DE 3783394 T2	06-05-1993
			DE 247983 T1	27-09-1990
			DK 215887 A	31-10-1987
			EP 0247983 A2	02-12-1987
			EP 0567201 A2	27-10-1993
			ES 2006457 T3	01-01-1994
			ES 2091971 T3	16-11-1996
			ES 2135443 T3	01-11-1999
			FI 871913 A ,B,	31-10-1987
			GR 89300058 T1	22-06-1989
			GR 3007434 T3	30-07-1993
			GR 3032101 T3	31-03-2000
			HK 52897 A	02-05-1997
			HK 135294 A	09-12-1994
			HR 920854 A1	31-10-1994
			HU 43954 A2	28-01-1988
			IE 61416 B	02-11-1994
			JP 1863556 C	08-08-1994
			JP 62258320 A	10-11-1987
			JP 5069807 B	01-10-1993
			JP 2740993 B2	15-04-1998
			JP 5294831 A	09-11-1993
			KR 9104579 B1	06-07-1991
			LT 1683 A ,B	25-07-1995
			LV 10357 A	20-02-1995

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PC1/SI 01/00031

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0496437	A		LV 10357 B	20-04-1996
			NO 174239 B	27-12-1993
			NZ 220096 A	26-04-1990
			PH 25701 A	18-09-1991
			PT 84785 A , B	01-05-1987
			SI 8710681 A8	31-10-1996
			SU 1820837 A3	07-06-1993
WO 9624375	A	15-08-1996	AU 689372 B2	26-03-1998
			AU 4682296 A	27-08-1996
			BR 9605111 A	07-10-1997
			CA 2186039 A1	15-08-1996
			CN 1148344 A	23-04-1997
			CZ 9602931 A3	12-11-1997
			EE 9600118 A	15-04-1997
			EP 0754061 A1	22-01-1997
			FI 963984 A	04-10-1996
			HR 960032 A1	31-10-1997
			HU 9603064 A2	28-08-1997
			IL 117041 A	16-07-2000
			JP 9511767 T	25-11-1997
			NO 964212 A	04-10-1996
			NZ 301408 A	28-07-1998
			PL 316684 A1	03-02-1997
			WO 9624375 A1	15-08-1996
			SK 126096 A3	07-05-1997
			TR 970235 T1	21-03-1997
			US 6136344 A	24-10-2000
			ZA 9600365 A	06-08-1996
US 5431917	A	11-07-1995	US 5264223 A	23-11-1993

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.